Connect with us


Kanabo becomes second cannabis company to list on the LSE



Fellow cannabis company MGC Pharma became the first to enter the market last week

This week, Kanabo Group Plc become the second cannabis company in history to list on the main market of the London Stock Exchange, just a week after MGC Pharma’s IPO.

Following a reverse takeover which saw Spinnaker Opportunities acquire Kanabo Research Ltd, the Israeli company, now called Kanabo Group Plc, has listed on the LSE.

Kanabo hoped to become the first cannabis company to list on the LSE but was pipped at the post by MGC Pharma, which announced its initial public offering on the 9th February.

Kanabo successfully completed its initial public offering (IPO) of £6 million yesterday. As with MGC Pharma, Kanabo was significantly oversubscribed, giving it a valuation of roughly £23.5 million on admission.

Its shares launched at 4.75p but by the end of the day, they had almost quadrupled in valued, closing at 20.5p, according to The Guardian.

Founder of Kanabo, Avihu Tamir believes this is a “game-changer” for the sector and demonstrates that the UK could be following in the footsteps of North America in its acceptance of medicinal cannabis.

“There is going to be a swift change in Europe. I think that what we saw starting in the US and Canada around like five years ago is now reaching Europe,” Tamir told Cannabis Health.

“Once you have the public market in a certain country being opened, you suddenly see the shift in how the cannabis industry is being perceived by decision-makers.”

Tamir takes Israel as an example, where medical cannabis has been legal since 2007.

“It was the first federally legal medical cannabis market in the world,” he continued.

“You would always see these articles; interesting stories about cannabis or someone famous that got their license. The story is similar to what you have now in the UK, with the problem of accessibility and orientation of medical health.

“Once you start to see [cannabis] companies going to a public market, everything changes because the story is moved to the mainstream, business sector. The discussion is different suddenly, it’s a legitimate business, it is not a drug anymore. It is a medicine.”

Kanabo seeks to provide an alternative solution to the smoking of medicinal cannabis flowers. Its flagship product, the VapePod, is the first-ever medically certified vaporiser for cannabis oils.

It can administer an accurate, measured dose of cannabis extract, which the company hopes will improve patient access and boost trust amongst medical professionals.

“The challenge is the physicians and medical establishments because we need to convince them that a vape is a medical route of administration,” Tamir explained.

“But with cannabis, physicians are actually prescribing flowers for smoking. [We are] bringing a medical device that is a metered dose, that is always the same. In the cartridge, you’re getting the same consistency of the formula; the same CBD levels and the same THC levels.”

In Israel, the company has been granted licences for further cannabis research and pre-clinical trials for insomnia and sleep disorders. The data from this research will, for the first time, produce bioavailability graphs for vape pens.

Tamir hopes that this will build further confidence in medical professionals who he says do not understand the unpredictability of oral administration.

He said: “When doctors see this information, they will understand that when you take in an inhalation, after three hours, the amount of cannabis your system is reduced to a very low amount.

“In oil consumption, it may be as much as eight hours.”

Outside of Israel, the company is currently selling products in the UK and Germany and says it is ready to scale up to meet market demands.

It recently launched a pilot programme for its non-THC product line in an effort to improve access to medical-grade cannabis products for people who are not able to get a prescription.

“We want to take the knowledge and experience we have in medical cannabis and give access to people that can’t get a prescription,” Tamir said.

“Our non-THC product line is pure hemp extracts, natural and makes our [products] accessible across the board in the UK and in Europe.”

Currently in advanced stages to receive the EU-registered CE mark, Kanabo is in talks with several distributors who have taken an interest in partnering in the EU.

Future products on the horizon for Kanabo include a second-generation medically certified device, new medicinal cannabis oils, and further clinical trials.


Australia lists first subsidised medical cannabis drug

Epidyolex has become the first medical cannabis product to be subsidised by the Australian Government.



Epidyolex is the first medical cannabis product to be subsidised by the Australian Government

The epilepsy drug, Epidyolex has become the first medical cannabis product to be subsidised by the Australian Government.

Australians living with the rare form of epilepsy known as Dravet syndrome, will now have access to the cannabis-derived drug via the country’s Pharmaceutical Benefits Scheme (PBS) for the first time.

As of 1 May, 2021, Epidyolex, which contains CBD, is listed on the PBS for patients with the treatment-resistant condition, to be used in combination with at least two other anti-epileptic medicines. 

Epidyolex is only the second medicinal cannabis drug registered for supply in Australia, and the first one to be subsidised by the Government on the PBS.

Dravet syndrome is a rare, genetic epileptic encephalopathy that gives rise to seizures which don’t respond well to the standard medications.

It is estimated that around 116 patients each year will benefit from the listing of Epidyolex, who might otherwise pay more than $24,000 per year for the treatment. 

They will now pay only $41.30 per script or $6.60 if they have a concession card.

According to a report by FreshLeaf Analytics published last year, there are now around 30,000 medical cannabis patients in Australia with “record-numbers” of doctors prescribing.

But as prescriptions are not covered under the PBS, they remain costly compared to conventional medicines and out of reach for many.

In a statement announcing the listing of Epidyolex, Australian Health Minister Greg Hunt said the Government’s commitment to ensuring patients can access affordable medicines “remains rock solid”. 


Continue Reading


Experts to explore the role of medical cannabis in women’s health

A line-up of leading experts will discuss how cannabis medicines can play a vital role in women’s health.



Many women are still unaware of female-specific health conditions such as pelvic inflammatory syndrome (PIS) or vulvodynia

Leading pain specialist, Dr Sally Ghazaleh will join a line-up of experts to discuss how cannabis medicines can play a vital role in women’s health.

The first of a four-part webinar series, taking place on Wednesday 12 May, will focus on the experience’s of women who have not felt supported by the current healthcare system – and how cannabis has helped them find relief from their conditions.

Dr Sally Ghazaleh, a pain specialist at Integro Medical Clinics, will join Sarah Higgins, clinical nurse specialist and women’s health lead at Cannabis Patient Advocacy Support Services (CPASS), alongside endometriosis patients Abby Hughes, outreach chair of PLEA (Patient-Led Engagement for Access) and Laura, author of The Endomonologues blog.

Dr Sally Ghazaleh

Dr Sally Ghazaleh is a pain management specialist

Aimed at patients, clinicians and the general public the webinar series, hosted by Cannabis Health, Integro Clinics and CPASS, aims to discuss the application of cannabis medicines in the management of complex female health conditions.

It will also highlight some of the wider issues and gender inequalities played out in the modern medical model.

Studies have shown that women’s pain is not acted on as quickly and is more likely to be dismissed than men’s, while many conditions can present differently in women than in men and therefore take longer to diagnose.

Many women are still unaware of female-specific health conditions such as pelvic inflammatory syndrome (PIS) or vulvodynia and can live with the symptoms for many years before they are correctly diagnosed and treated.

Some patients are now reporting that they have found cannabis medicines to be helpful in the management of their health conditions.

Dr Ghazaleh, a consultant at Whittington Hospital and the National Hospital of Neurology and Neurosurgery in London, joined Integro Clinics as a prescriber of medical cannabis in January. 

She specialises in managing patients with a wide range of pain conditions and has a particular interest in bladder and abdominal pain in women, and women’s health in general.

The free webinar will take place on Wednesday 12 May at 7pm.

The event is hosted by Cannabis Health, Integro Medical Clinics and CPASS, sign up for free here

If you would like further information, or to make an appointment for a medical consultation with Dr Sally Ghazaleh please contact Integro Clinics:  


Twitter: @clinicsintegro


Continue Reading


Cannabis treatment to be trialled for common pet health issue

Trials of a synthetic cannabinoid treatment for common eye problems in dogs have been given the green light.



close up of dog
Eye ulcers are one of the most common health problems in dogs

Trials of a cannabis-derived treatment which could rid dogs of common and potentially blinding eye ulcers, have been given the go-ahead.

Tetra Bio-Pharma will continue with clinical trials on its synthetic cannabinoid products in the hope of finding an easy-to-use medication for pets with the painful condition.

Eye ulcers are one of the most common health problems in dogs and, if left untreated, can lead to the loss of an eye.

The condition is particularly common among a number of breeds which have gained in popularity in recents years, including pugs, bulldogs and West Highland terriers.

Initial symptoms include a red and aggravated eye and the condition often needs to be treated by a vet.

Progress has been slowed due to the Covid-19 pandemic but now the company is looking to forge ahead with the first-of-its-kind trial after receiving authorisation from the Veterinary Drugs Directorate of Health Canada.

The company is also engage in developing a treatment for acute respiratory distress syndrome (ARDS) which could eventually be used to treat people suffering with the coronavirus.

The trials of PPP-003v, Tetra’s proprietary veterinary ocular formulation for treating ocular pain and inflammation in companion animals, could see Tetra find a way into a market expect to be worth over $220 million by 2026.

Dr Guy Chamberland, CEO and CRO of Tetra Bio-Pharma, said: “The PPP-003 program, including PPP-003v, represents a significant opportunity for Tetra since there is a substantial unmet medical need for painful inflammatory eye disease.”

He added: “We are pleased with this regulatory authorisation and the ability to re-activate the trial.

“While the active pharmaceutical ingredient used in the PPP-003v drug formulation is the same as the one used in ARDS-003, Tetra’s innovative immunomodulator drug concurrently being developed for Covid-19, there is a major difference with how the drug is delivered.

“PPP-003v is intended to be used as a topical medication and is delivered as a sterile eye drop and ointment, while ARDS-003 is a sterile injectable nano-emulsion finished drug product.”

Continue Reading